MetaVia Inc - Company Profile
Powered by 
All the sales intelligence you need on MetaVia Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MetaVia Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MetaVia Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MetaVia Inc (MetaVia), a subsidiary of Dong-A ST Co Ltd, focuses on developing and commercializing innovative therapeutics for cardiometabolic diseases. The company’s strengths include its robust intellectual property portfolio, Focus on R&D activities and lead product candidate, DA-1241. However, a Clinical Trial Suspension remains a significant concern. Growth opportunities exist through the Type 2 Diabetes, the market potential for metabolic dysfunction-associated steatohepatitis, and various strategic agreements. Nonetheless, the company faces challenges from intense competition, stringent regulations, and rapid technological changes, which could negatively impact its business, operating results, and financial position.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer